In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...